{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T05:30:23Z","timestamp":1720675823204},"reference-count":30,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["La Presse M\u00e9dicale"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1016\/j.lpm.2013.06.007","type":"journal-article","created":{"date-parts":[[2013,8,21]],"date-time":"2013-08-21T23:15:33Z","timestamp":1377126933000},"page":"1239-1245","source":"Crossref","is-referenced-by-count":2,"special_numbering":"P1","title":["Traitement antithrombotique et cancer"],"prefix":"10.1016","volume":"42","author":[{"given":"Guy","family":"Meyer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Sanchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Planquette","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.lpm.2013.06.007_bib0005","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1001\/jama.293.6.715","article-title":"Malignancies, prothrombotic mutations, and the risk of venous thrombosis","volume":"293","author":"Blom","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.lpm.2013.06.007_bib0010","doi-asserted-by":"crossref","first-page":"4839","DOI":"10.1200\/JCO.2009.22.3271","article-title":"Assessing risk of venous thromboembolism in the patient with cancer","volume":"27","author":"Khorana","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lpm.2013.06.007_bib0015","doi-asserted-by":"crossref","first-page":"2703","DOI":"10.1182\/blood-2008-02-142422","article-title":"High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS)","volume":"112","author":"Ay","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.lpm.2013.06.007_bib0020","doi-asserted-by":"crossref","first-page":"4902","DOI":"10.1182\/blood-2007-10-116327","article-title":"Development and validation of a predictive model for chemotherapy-associated thrombosis","volume":"111","author":"Khorana","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.lpm.2013.06.007_bib0025","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/S0140-6736(94)90008-6","article-title":"Double-blind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer","volume":"343","author":"Levine","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.lpm.2013.06.007_bib0030","doi-asserted-by":"crossref","first-page":"401S","DOI":"10.1378\/chest.126.3_suppl.401S","article-title":"Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy","volume":"126","author":"Buller","year":"2004","journal-title":"Chest"},{"key":"10.1016\/j.lpm.2013.06.007_bib0035","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/S1470-2045(09)70232-3","article-title":"Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study","volume":"10","author":"Agnelli","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.lpm.2013.06.007_bib0040","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa1108898","article-title":"Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer","volume":"366","author":"Agnelli","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2013.06.007_bib0045","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1182\/blood-2002-01-0108","article-title":"Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis","volume":"100","author":"Prandoni","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.lpm.2013.06.007_bib0050","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1177\/1076029606293692","article-title":"Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period","volume":"12","author":"Deitcher","year":"2006","journal-title":"Clin Appl Thromb Hemost"},{"key":"10.1016\/j.lpm.2013.06.007_bib0055","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/j.amjmed.2006.02.022","article-title":"Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer","volume":"119","author":"Hull","year":"2006","journal-title":"Am J Med"},{"key":"10.1016\/j.lpm.2013.06.007_bib0060","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1056\/NEJMoa025313","article-title":"Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer","volume":"349","author":"Lee","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2013.06.007_bib0065","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1001\/archinte.162.15.1729","article-title":"Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study","volume":"162","author":"Meyer","year":"2002","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.lpm.2013.06.007_bib0070","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.critrevonc.2008.12.004","article-title":"French national guidelines for the treatment of venous thromboembolism in patients with cancer: report from the working group","volume":"73","author":"Farge","year":"2010","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.lpm.2013.06.007_bib0075","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1111\/j.1538-7836.2009.03326.x","article-title":"Dose escalation of low-molecular weight heparin to manage recurrent venous thromboembolic events despite systemic anticoagulation in cancer patients","volume":"7","author":"Carrier","year":"2009","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.lpm.2013.06.007_bib0080","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1111\/j.1538-7836.2012.04868.x","article-title":"Risk factors and clinical outcome of unsuspected pulmonary embolism in cancer patients: a case-control study","volume":"10","author":"Sahut D\u2019Izarn","year":"2012","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.lpm.2013.06.007_bib0085","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1200\/JCO.2010.32.3220","article-title":"Venous thromboembolic events with chemotherapy plus bevacizumab: a pooled analysis of patients in randomized phase II and III studies","volume":"29","author":"Hurwitz","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lpm.2013.06.007_bib0090","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/sj.bjc.6606074","article-title":"Bleeding events in bevacizumab-treated cancer patients who received full-dose anticoagulation and remained on study","volume":"104","author":"Leighl","year":"2011","journal-title":"Br J Cancer"},{"key":"10.1016\/j.lpm.2013.06.007_bib0095","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1056\/NEJMoa1113572","article-title":"Oral rivaroxaban for the treatment of symptomatic pulmonary embolism","volume":"366","author":"Buller","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2013.06.007_bib0100","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa0906598","article-title":"Dabigatran versus warfarin in the treatment of acute venous thromboembolism","volume":"361","author":"Schulman","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2013.06.007_bib0105","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1055\/s-2007-991531","article-title":"The role of tissue factor pathway inhibitor in tumor growth and metastasis","volume":"33","author":"Amirkhosravi","year":"2007","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.lpm.2013.06.007_bib0110","doi-asserted-by":"crossref","first-page":"4902","DOI":"10.1200\/JCO.2009.22.4584","article-title":"Impact of venous thromboembolism and anticoagulation on cancer and cancer survival","volume":"27","author":"Kuderer","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lpm.2013.06.007_bib0115","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1160\/TH04-02-0069","article-title":"Inhibition of endothelial cell tube formation by the low-molecular weight heparin, tinzaparin, is mediated by tissue factor pathway inhibitor","volume":"92","author":"Mousa","year":"2004","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.lpm.2013.06.007_bib0120","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1160\/TH05-07-0515","article-title":"The ability of different forms of heparins to suppress P-selectin function in vitro correlates to their inhibitory capacity on bloodborne metastasis in vivo","volume":"95","author":"Ludwig","year":"2006","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.lpm.2013.06.007_bib0125","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1160\/TH06-05-0289","article-title":"Anti-metastatic effect of a non-anticoagulant low-molecular-weight heparin versus the standard low-molecular-weight heparin, enoxaparin","volume":"96","author":"Mousa","year":"2006","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.lpm.2013.06.007_bib0130","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1056\/NEJMe1113672","article-title":"Routine heparin for patients with cancer? One answer, more questions","volume":"366","author":"Akl","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2013.06.007_bib0135","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/j.1538-7836.2010.04131.x","article-title":"The platelet contribution to cancer progression","volume":"9","author":"Bambace","year":"2011","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.lpm.2013.06.007_bib0140","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1016\/S0140-6736(11)61720-0","article-title":"Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51\u00a0randomised controlled trials","volume":"379","author":"Rothwell","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.lpm.2013.06.007_bib0145","first-page":"297","article-title":"Clinical evidence for the use of aspirin in the treatment of cancer","volume":"7","author":"Langley","year":"2013","journal-title":"Ecancermedicalscience"},{"key":"10.1016\/j.lpm.2013.06.007_bib0150","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1016\/S0140-6736(11)61049-0","article-title":"Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2\u00a0randomised controlled trial","volume":"378","author":"Burn","year":"2012","journal-title":"Lancet"}],"container-title":["La Presse M\u00e9dicale"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498213006465?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498213006465?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,21]],"date-time":"2019-07-21T12:47:13Z","timestamp":1563713233000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0755498213006465"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9]]},"references-count":30,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["S0755498213006465"],"URL":"https:\/\/doi.org\/10.1016\/j.lpm.2013.06.007","relation":{},"ISSN":["0755-4982"],"issn-type":[{"value":"0755-4982","type":"print"}],"subject":[],"published":{"date-parts":[[2013,9]]}}}